Kura Oncology Correlations

KURA
 Stock
  

USD 13.07  0.59  4.32%   

The correlation of Kura Oncology is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kura Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kura Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Please see Correlation Analysis.
  
The ability to find closely correlated positions to Kura Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kura Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kura Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kura Oncology to buy it.

Moving together with Kura Oncology

+0.65NVONovo Nordisk ASPairCorr
+0.62NONOFNOVO NORDISK ASPairCorr
+0.67MRNAModernaPairCorr
+0.69BNTXBiontech Se ADRPairCorr
+0.74OSTKOOVERSTOCK COM INCPairCorr
+0.89PFEPfizer IncPairCorr

Moving against Kura Oncology

-0.67ADRTAult Disruptive TechPairCorr
-0.58ASCLFAscletis PharmaPairCorr
-0.57REGNRegeneron PharmaceuticalsPairCorr
-0.59WMTWalmartPairCorr

Related Correlations

BDC
ZBRA
COMM
HPE
LITE
BDC
0.560.720.70.64
BDC
ZBRA
0.560.010.930.92
ZBRA
COMM
0.720.010.140.05
COMM
HPE
0.70.930.140.97
HPE
LITE
0.640.920.050.97
LITE
BDC
ZBRA
COMM
HPE
LITE
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Correlation Matchups

The Correlation Coefficient is a useful tool to identify correlated or non-correlated securities, which is essential in developing a diversified portfolio. It tells us the relationship between two positions you have in your portfolio or considering acquiring. Over a given time period, the two securities movetogether when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.
High positive correlations   
LITEHPE
HPEZBRA
LITEZBRA
COMMBDC
HPEBDC
LITEBDC
  

Kura Oncology Competition Risk-Adjusted Indicators

Nowadays, there is a big difference between Kura Oncology Stock performing well and Kura Oncology company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Kura Oncology's multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kura Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Kura Oncology Corporate Directors

Kura Oncology corporate directors refer to members of a Kura Oncology board of directors. The board of directors generally takes responsibility for the Kura Oncology's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Kura Oncology's board members must vote for the resolution. The Kura Oncology board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Steven Stein - DirectorProfile
Thomas Malley - DirectorProfile
Mary Szela - DirectorProfile
Faheem Hasnain - Independent DirectorProfile

Invested in Kura Oncology?

The danger of trading Kura Oncology is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Kura Oncology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Kura Oncology. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Kura Oncology is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Correlation Analysis. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for analysis

When running Kura Oncology price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Kura Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.